Stockpolly
Search
KYNB · NASDAQ · Biotechnology

Kyntra Bio (KYNB)

Develops CD46-targeted cancer therapies and roxadustat for anemia in lower-risk myelodysplastic syndromes.

$8.57
Pre-market−0.01 (−0.12%)
At close$8.58(+7.92%)
Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Insiders5 holders · as of Jun 9, 20262.21%89.4K shares
Strategic holders1 holder · as of May 15, 20269.88%400.0K shares
Otherremainder87.91%3.56M shares

4.05M company shares as of Sep 3, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
Armistice Capital, LLCStrategic
9.88%400,00013Gfiled May 15, 2026 ↗
James A. SchoeneckInsiderdirector
0.98%39,666Form 4filed Jul 2, 2025 ↗
Thane WettigInsiderdirector, officer: CEO
0.67%27,005Form 4filed Jun 9, 2026 ↗
Christine ChungInsiderofficer: SVP, CHINA OPERATIONS
0.29%11,796Form 4filed Mar 7, 2025 ↗
Juan GrahamInsiderofficer: CHIEF FINANCIAL OFFICER
0.16%6,595Form 4filed Dec 9, 2024 ↗
David DeLuciaInsiderofficer: Chief Financial Officer
0.11%4,377Form 4filed Jun 9, 2026 ↗
Rory B. Riggs1Insiderdirector
0.39%15,830Form 4filed May 28, 2021 ↗
Enrique A. Conterno2Insiderdirector, officer: Chief Executive Officer
0.37%14,989Form 4filed Jul 10, 2023 ↗
Pat Cotroneo3Insiderofficer: Executive Advisor & Former CFO
0.27%10,981Form 4filed Sep 9, 2021 ↗
K. Peony Yu4Insiderofficer: Chief Medical Officer
0.19%7,692Form 4filed Dec 17, 2020 ↗
Jorma Routti5Insiderdirector
0.16%6,462Form 4filed Mar 27, 2019 ↗
Mark Eisner6Insiderofficer: EVP, Chief Medical Officer
0.16%6,397Form 4filed Sep 8, 2023 ↗
Elias Kouchakji7Insiderofficer: SVP, Clinical Dev, Drug Safety
0.15%5,894Form 4filed Mar 10, 2021 ↗
Roberto Pedro Rosenkranz8Insiderdirector
0.09%3,844Form 4filed Jun 11, 2020 ↗
Deyaa Adib9Insiderofficer: Chief Medical Officer
0.08%3,285Form 4filed Jun 13, 2024 ↗
Toshinari Tamura10Insiderdirector
0.06%2,256Form 4filed Jun 7, 2019 ↗
Thomas B. Neff11Insiderdirector, officer: Chief Executive Officer
0.04%1,770Form 4filed Aug 23, 2019 ↗
Thomas F. Jr Kearns12Insiderdirector
0.04%1,591Form 4filed Sep 17, 2021 ↗
Kalevi Kurkijarvi1Insiderdirector
0.04%1,512Form 4filed May 28, 2021 ↗
Jeffrey L. Edwards13Insiderdirector
0.03%1,359Form 4filed Jun 9, 2023 ↗
Maykin Ho13Insiderdirector
0.03%1,260Form 4filed Jun 9, 2023 ↗
Suzanne Blaug13Insiderdirector
0.03%1,184Form 4filed Jun 9, 2023 ↗
Jeffrey William Henderson14Insiderdirector
0.03%1,155Form 4filed Sep 6, 2023 ↗
Gerald Lema13Insiderdirector
0.03%1,151Form 4filed Jun 9, 2023 ↗
Benjamin Cravatt13Insiderdirector
0.03%1,149Form 4filed Jun 9, 2023 ↗
  1. Last filed May 28, 2021; leaving the company requires no filing. Not in the bar.
  2. Last filed Jul 10, 2023; leaving the company requires no filing. Not in the bar.
  3. Last filed Sep 9, 2021; leaving the company requires no filing. Not in the bar.
  4. Last filed Dec 17, 2020; leaving the company requires no filing. Not in the bar.
  5. Last filed Mar 27, 2019; leaving the company requires no filing. Not in the bar.
  6. Last filed Sep 8, 2023; leaving the company requires no filing. Not in the bar.
  7. Last filed Mar 10, 2021; leaving the company requires no filing. Not in the bar.
  8. Last filed Jun 11, 2020; leaving the company requires no filing. Not in the bar.
  9. Last filed Jun 13, 2024; leaving the company requires no filing. Not in the bar.
  10. Last filed Jun 7, 2019; leaving the company requires no filing. Not in the bar.
  11. Last filed Aug 23, 2019; leaving the company requires no filing. Not in the bar.
  12. Last filed Sep 17, 2021; leaving the company requires no filing. Not in the bar.
  13. Last filed Jun 9, 2023; leaving the company requires no filing. Not in the bar.
  14. Last filed Sep 6, 2023; leaving the company requires no filing. Not in the bar.

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Armistice Capital, LLC9.88%400.0K13GMay 15, 2026 ↗

Insider tradesForm 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
May 14, 2026
Thane Wettigdirector, officer: CEO
Purchase · 2 lots5,600$7.0927,203
Nov 13, 2025
Thane Wettigdirector, officer: CEO
Purchase1,000$9.1822,239
Nov 17, 2025
Thane Wettigdirector, officer: CEO
Purchase2,700$9.1024,939

CongressHouse and Senate disclosures

Not reported.